Q5119 HCPCS Code Guide: Ruxience Billing, Units, and Coding Requirements

Ruxience is a biosimilar version of rituximab, and is coded as the Q5119 HCPCS code. Reporting accurately depends on using the right units, identifying the product, using the right diagnosis codes, and there has to be supporting documentation.

The billers should distinguish Ruxience from all other brands of rituximab because this is a drug code. The manner in which the claim is prepared depends on the drug administered, dosage, and the billing setting and the requirements of the payers.

This guide provides a description of this code billing, units, wastage, modifiers, diagnosis coding, documentation and reimbursement considerations.

What Is the Q5119 HCPCS Code?

Ruxience’s code is Q5119 and it is a Level II HCPCS code. The code that CMS uses to describe the product, Injection, rituximab-pvvr, biosimilar, (Ruxience), 10 mg. The code is for 10mg of rituximab-pvvr and should therefore be the same amount of drug as recorded.

In the current HCPCS, CMS still reports as Ruxience, 10 mg the code. This code is also on the 2026 PACE excluded-services list for the drug Ruxience, 10 mg.

What Drug Does Q5119 Represent?

Ruxience is the brand name for this code which is the drug known as rituximab-pvvr. It is a biosimilar to rituximab, and is used intravenously for its indicated uses. The product comes in single dose vial presentations. CMS application information differentiates presentations: 100mg/10mL and 500mg/50mL; vial strength and billing units are important. This is important when billing since the HCPCS unit is per 10 mg, not the vial size. All units reported should be those documented that are administered or disposed of appropriately.

Q5119 Units: How Should They Be Calculated?

The documented billable amount should be rounded to 10mg units so this code is 10mg per billing unit. The fundamental computation is 10 times the amount of milligrams in the billable amount, to get the number of HCPCS units.

Formula:

units = Total billable milligrams ÷ 10 mg

For example, if 500 mg is administered:

500 mg ÷ 10 mg = 50 units

If 1,000 mg is administered:

1,000 mg ÷ 10 mg = 100 units

When the documented dosage does not divide evenly into 10 mg units, applicable Medicare billing guidance should be followed for reporting and rounding. The clinical dose itself must always come from the patient’s documented treatment regimen.

Unit Examples

The clinical dose should always come from the patient’s documented treatment regimen. Coding staff should not determine the therapeutic dose independently.

Q5119 Dosage and Billing Units

The quantity given and the number of billing units are different but related measurements. The HCPCS code will translate the amount of medication into billable units, and the medical record will show the amount. A documented dose of 500mg is equal to 50 units. This conversion should be documented on the medication administration record and other appropriate paperwork.

The difference is particularly significant if there is more medicine in the vial than the patient will receive. Billing staff should verify the prescribed dose, administered dose, quantity dispensed and quantity used prior to claiming.

A billing team should verify three quantities:

1. The prescribed dose.
2. The amount actually administered.
3. The amount remaining and actually discarded.

These quantities should agree with the medication administration record and supporting documentation.

Q5119 and Drug Wastage

Ruxience may be supplied in single-dose containers. When a Medicare patient receives less than the amount in a single-dose container, the remaining amount may qualify for payment when it is actually discarded and all applicable requirements are met.

CMS requires discarded drug amounts to be reported using the JW modifier when applicable. The discarded amount must be reported separately from the administered amount, with documentation supporting the quantity discarded.

For example, assume:

• One vial contains 500 mg.
• The patient receives 450 mg.
• The remaining 50 mg is discarded.

The administered amount equals:

450 mg ÷ 10 mg = 45 units

The discarded amount equals:

50 mg ÷ 10 mg = 5 units

The Medicare claim may therefore contain separate reporting for the administered and discarded amounts when the JW requirements apply. The medical record should clearly support the administered dose, discarded amount, and vial quantity.

Q5119 JW and JZ Modifier Requirements

Medicare’s JW and JZ policies are important for eligible single-dose container drugs. These modifiers distinguish medication that was discarded from medication where no amount was discarded.

The JW modifier identifies drug amounts discarded from a single-dose container. The discarded medication must actually be wasted and cannot be used for another patient.

The JZ modifier indicates that no amount was discarded. Medicare requires JZ reporting for applicable single-dose container drugs when there is no discarded amount.

Example With Drug Waste

Let’s take a look at an Example With Drug Waste.

If the entire 500 mg is administered with no waste, applicable Medicare reporting would generally use:

If a patient was given 450 mg from a single dose vial containing a total of 500 mg, then he or she took one-half of the dose.

Q5119 Diagnosis Coding

Q5119 is a drug code, so it does not replace the ICD-10-CM diagnosis describing why treatment was provided. The diagnosis reported on the claim should reflect the patient’s documented condition and support the medical necessity of the treatment.

CMS coverage materials list this code alongside other rituximab codes for multiple covered conditions. These include certain hematologic, autoimmune, transplant-related, and other conditions depending on the applicable Medicare coverage policy. Coders should avoid selecting a diagnosis simply because it frequently appears with rituximab. The diagnosis must instead come from the patient’s documentation and applicable coverage requirements.

When reviewing a claim, consider:

• The provider’s documented diagnosis.
• The treatment indication.
• Applicable Medicare coverage policies.
• Local MAC requirements.
• Payer-specific medical necessity rules.

The diagnosis must accurately represent the patient’s condition and the reason for treatment.

Common Diagnosis Considerations for Q5119

Rituximab products can be used for different clinical conditions, so there is no single ICD-10-CM code that universally accompanies this code. The appropriate diagnosis depends on the documented indication and applicable coverage requirements.

Depending on the documented indication, relevant diagnosis categories may include:

• Certain non-Hodgkin lymphomas.
• Chronic lymphocytic leukemia.
• Rheumatoid arthritis.
• Granulomatosis with polyangiitis.
• Microscopic polyangiitis.
• Certain immune-mediated conditions.
• Certain transplant-related conditions.

The exact ICD-10-CM code should come from the current documentation and applicable coverage policy. For Medicare claims, CMS coverage articles can specify which diagnoses support rituximab-related services.

Q5119 Medical Necessity Requirements

Medical necessity is an important part of drug claim review because the documentation must connect the treatment with the patient’s condition. Records should also support the dosage, product, administration, and treatment circumstances reported on the claim.

The documentation should connect the prescribed Ruxience treatment with the patient’s diagnosed condition. It should also support the dosage and administration provided.

Useful documentation can include:

• Patient diagnosis.
• Treatment indication.
• Medication name.
• Dose ordered.
• Dose administered.
• Administration date.
• Route of administration.
• Start and completion information.
• Medication administration record.
• Amount discarded, when applicable.
• Provider documentation supporting medical necessity.

Additional records may be needed when the payer requests them during review.

Q5119 Administration Coding

This code identifies the drug itself and does not represent the complete infusion service. When an infusion is provided, the appropriate administration service should be evaluated separately under the applicable coding and payment rules.

The administration code depends on factors such as:

• Initial versus subsequent service.
• Additional infusion services.
• Infusion duration.
• Route of administration.
• Services performed during the encounter.
• Payer-specific billing requirements.

The drug code and administration code should therefore be reviewed separately. Reporting this code alone does not automatically represent the complete infusion administration service.

Q5119 Documentation Requirements

Accurate documentation helps establish that the billed drug units match the treatment provided. It also supports modifier reporting, medical necessity, and payer review when additional records are requested.

When discarded drug billing applies, documentation should support the actual administered amount, wasted amount, and labeled vial quantity. These records provide a clear basis for the units and modifiers reported on the claim.

Q5119 Medicare Reimbursement

Reimbursement is not represented by one permanent dollar amount. Medicare payment can change according to the applicable payment methodology, pricing updates, and date of service. Medicare generally uses ASP-based payment limits for separately payable Part B drugs and biological products. CMS publishes payment limits through quarterly Medicare Part B Drug Payment Limit Files.

For biosimilars, Medicare generally calculates the payment limit using the biosimilar’s ASP plus an add-on based on the reference biological product’s ASP. Qualifying biosimilars can receive a temporary increased add-on of 8 percent of the reference product’s ASP during the applicable five-year period.

Therefore, the reimbursement associated with this HCPCS code can change between payment quarters. Billing teams should use the applicable Medicare payment limit file for the date of service rather than relying on an older reimbursement figure.

What Affects Q5119 Reimbursement?

Several factors can affect the amount ultimately paid for this code. The allowed amount can vary based on the payer, treatment setting, payment methodology, and applicable coverage requirements.

These include:

• Medicare versus commercial insurance.
• Place of service.
• Payment methodology.
• Current ASP information.
• Applicable payer contract.
• Coverage status.
• Units reported.
• Drug wastage.
• Modifiers.
• Deductible and coinsurance.
• Prior authorization requirements.
• Claim edits.

The billed charge is not necessarily the same as the payer’s allowed amount. Medicare Part B payment limits can also change periodically as CMS updates applicable pricing information.

Q5119 in Physician Office Billing

Physician offices may report this code when the product is separately payable and coverage requirements are met. The claim should accurately identify the administered product, dosage, diagnosis, applicable modifiers, and related administration services.

The claim should accurately identify:

• The administered Ruxience product.
• Correct units.
• Applicable modifiers.
• Appropriate diagnosis codes.
• Administration services.
• Place of service.
• Supporting documentation.

The office should also verify whether the payer requires prior authorization or other utilization controls. Commercial insurers may apply rules that differ from traditional Medicare, so payer-specific instructions should be reviewed before submission.

Q5119 Hospital Outpatient Billing

Hospital outpatient claims can involve additional claim elements compared with professional claims. The facility may need to report the drug with revenue and claim information that differs from physician office billing.

The hospital may need to report information such as:

• HCPCS code.
• Revenue code.
• Units.
• Modifiers.
• Diagnosis codes.
• Administration services.
• Drug acquisition documentation when required.
• Other facility-specific claim information.

The exact reporting requirements depend on the payer and payment system. Hospitals should therefore verify current facility billing instructions before submitting claims.

Q5119 and Biosimilar Product Selection

Ruxience is identified by the drug name rituximab-pvvr. If using another rituximab biosimilar, the code may be different; therefore, product identification is key to choosing the code. For instance, Truxima is listed in CMS’ drug and device inventory under the code Q5115, while Riabni is under the code Q5123. Rituximab is identified by the applicable descriptor in J9312.

The actual product administered should drive product-specific code selection. A payer’s preferred biosimilar does not automatically determine which HCPCS code should be reported.

Q5119 vs J9312

Q5119 and J9312 both relate to rituximab products, but they are not interchangeable. Q5119 specifically identifies rituximab-pvvr, Ruxience, 10 mg, while J9312 identifies rituximab under its own HCPCS descriptor. The distinction is important because the HCPCS code must accurately identify the product administered. Reporting J9312 instead of Q5119 could misrepresent the specific drug documented in the medical record.

Q5119 vs Q5115

Q5119 and Q5115 both identify rituximab biosimilars, but they represent different products. This code identifies Ruxience, while Q5115 identifies Truxima.

• Q5119: Rituximab-pvvr, Ruxience.
• Q5115: Rituximab-abbs, Truxima.

CMS lists both codes separately in its coverage and HCPCS materials. This distinction is important because reporting another biosimilar’s code would not accurately describe the drug administered.

Common Q5119 Billing Errors

Several mistakes can create claim delays or payment problems. Most involve product selection, unit calculation, wastage reporting, diagnosis coding, or failure to follow current payer requirements.

Reporting the Wrong Rituximab Code

Rituximab biosimilars have product-specific HCPCS codes. Confirm the exact product before selecting the code.

Miscalculating Units

This code is billed in 10 mg increments. Convert the documented milligram amount into the appropriate number of units.

Ignoring Drug Waste

When an applicable single-dose container has discarded medication, Medicare requires appropriate JW reporting.

Omitting JZ When Required

If no amount is discarded from an applicable single-dose container, Medicare requires JZ reporting under its applicable policy.

Using Unsupported Diagnosis Codes

The diagnosis should represent the documented condition and support the medical necessity of treatment.

Confusing Drug and Administration Coding

This code identifies the drug. It does not automatically represent the infusion administration service.

Using Outdated Payment Rates

Medicare payment limits can change quarterly. Use the applicable payment file for the relevant date of service.

Practical Q5119 Billing Example

Consider a patient receiving Ruxience during an outpatient infusion visit. The documentation shows a 500 mg dose, with the full contents of a 500 mg single-dose vial administered and no medication discarded.

The documentation shows:

• Ruxience administered: 500 mg.
• Single-dose vial used: 500 mg.
• Drug discarded: 0 mg.
• Diagnosis: documented condition supporting treatment.
• Administration: intravenous infusion.

Step 1: Calculate Units

This code represents 10 mg per billing unit.

500 mg ÷ 10 mg = 50 units

Therefore, the drug claim reports 50 units.

Step 2: Review Wastage

No medicines were discarded. The JZ modifier is used for applicable Medicare claims where there is no amount discarded when single dose containers are used.

Step 3: Verify Diagnosis

The diagnosis should match the provider’s documented treatment indication. It should also satisfy applicable payer coverage and medical necessity requirements.

Step 4: Review Administration Coding

The appropriate infusion administration service should be evaluated separately. The correct administration code depends on the documented services and applicable coding rules.

Step 5: Check Payment Rules

The billing team should verify the current payer payment methodology and any applicable authorization requirements. Medicare claims should use the payment rules applicable to the date of service. This workflow helps keep drug, diagnosis, administration, and payment reporting aligned.

Key Takeaways:

The Q5119 HCPCS code represents rituximab-pvvr, biosimilar, Ruxience, 10 mg. Accurate billing begins with confirming that Ruxience was the actual product administered and converting the documented dosage into the correct billing units. Medicare also has specific requirements for discarded drug reporting. JW identifies eligible discarded amounts, while JZ indicates no discarded amount for applicable single-dose container claims.

Do not consider reimbursement to be a set amount as Medicare payment limits can adjust based on quarterly ASP changes and applicable biosimilar payment policies. Rules for Payers may also impact the final allowed amount. To ensure accurate coding, be sure to check the current HCPCS descriptor, payment limit, coverage policy, modifier requirements and payer specific billing instructions for the date of service.

Frequently Asked Questions